Tardive Dyskinesia Market to Grow Rapidly at a CAGR of 8.1% During the Forecast Period (2026-2036) | DelveInsight
The market for tardive dyskinesia is anticipated to increase during the forecast period (2026–2036), owing to improved diagnosis, treatment advancements, aging demographics, increased awareness, the launch of emerging therapies such as NBI-1065890 (Neurocrine Biosciences), Bevantolol hydrochloride; SOM3355 (SOM…
News provided by PR Newswire.
